Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Vinod S Hegade, David E J Jones, Gideon M Hirschfield

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)
228 Downloads (Pure)

Abstract

Bile acids (BAs) have gained mainstream attention since the discovery of their key role as signalling molecules in health and disease. The apical sodium-dependent transporter (ASBT) protein located in the terminal ileum plays an important physiological role in the enterohepatic circulation of BAs and therefore essential for the BA homeostasis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), the 2 most common cholestatic liver diseases are characterised by altered BA flow and BA composition, which contribute to disease progression and symptom (pruritus) development. Therefore, changing the circulating BA pool in patients with PBC and PSC may have therapeutic implications. To this end, pharmacological inhibition of ASBT is fast emerging as an interesting target. In this review, we discuss the recent evidence for potential therapeutic use of ASBT inhibitors to treat PBC and PSC patients.

Original languageEnglish
Pages (from-to)267-274
Number of pages8
JournalDigestive Diseases
Volume35
Issue number3
Early online date1 Mar 2017
DOIs
Publication statusE-pub ahead of print - 1 Mar 2017

Keywords

  • Animals
  • Cholangitis, Sclerosing
  • Humans
  • Liver Cirrhosis, Biliary
  • Membrane Transport Proteins
  • Models, Biological
  • Peptides
  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis'. Together they form a unique fingerprint.

Cite this